Business Context and Reporting Period
Aardvark Therapeutics, Inc. (AARD) filed a Form 8-K on August 11, 2026, to report financial results for the second quarter ended June 30, 2026. The company is an emerging growth company incorporated in Delaware with principal executive offices in San Diego, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that a press release containing these details is furnished as Exhibit 99.1, but the specific financial data is not embedded in the text of the 8-K itself.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
Management provided business updates alongside the financial results, though the specific content of these updates is not detailed in the filing text. The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 financial figures and cash runway.
- Verify the details of the "business updates" mentioned in the press release.
- Confirm the company's status as an emerging growth company and any implications for financial reporting standards.
- Check for any forward-looking statements or guidance provided in the press release that are not included in this 8-K summary.